Global Growth Companies With Up To 29% Insider Ownership
As global markets navigate the complexities of Middle East tensions and energy market volatility, growth stocks have shown resilience, with sectors like information technology leading the charge in recent weeks. In this context, companies with high insider ownership can be particularly appealing to investors seeking alignment between management and shareholder interests.
Top 10 Growth Companies With High Insider Ownership Globally
| Name | Insider Ownership | Earnings Growth |
| Zhejiang Taotao Vehicles (SZSE:301345) | 27.9% | 31.5% |
| Shanghai Biren Technology (SEHK:6082) | 11% | 116.9% |
| Seojin SystemLtd (KOSDAQ:A178320) | 22% | 110.6% |
| Meitu (SEHK:1357) | 22.8% | 31.4% |
| Meiko Electronics (TSE:6787) | 19.2% | 27.6% |
| KebNi (OM:KEBNI B) | 11.8% | 90.9% |
| HUMAN MADE (TSE:456A) | 23.9% | 23.4% |
| Gold Circuit Electronics (TWSE:2368) | 30.1% | 38.2% |
| CD Projekt (WSE:CDR) | 35.2% | 29.7% |
| Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 14.1% | 40.4% |
Below we spotlight a couple of our favorites from our exclusive screener.
Yantai China Pet Foods (SZSE:002891)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Yantai China Pet Foods Co., Ltd. and its subsidiaries produce and sell pet food products both in China and internationally, with a market cap of CN¥9.09 billion.
Operations: The company generates revenue primarily from its Pet Food & Supplies segment, totaling CN¥5.43 billion.
Insider Ownership: 23.9%
Yantai China Pet Foods demonstrates characteristics of a growth company, with earnings forecast to grow significantly at 27.42% per year, outpacing the broader Chinese market. Despite trading well below its estimated fair value, recent financials show a decline in profit margins from 9.1% to 6.1%. The company's recent share buyback and dividend affirmations highlight active capital management but also indicate challenges in sustaining dividends through free cash flows.
- Click here and access our complete growth analysis report to understand the dynamics of Yantai China Pet Foods.
- Upon reviewing our latest valuation report, Yantai China Pet Foods' share price might be too pessimistic.
BMC Medical (SZSE:301367)
Simply Wall St Growth Rating: ★★★★★☆
Overview: BMC Medical Co., Ltd. focuses on the research, development, manufacturing, and supply of medical equipment and consumables for respiratory health in China and internationally, with a market cap of CN¥5.72 billion.
Operations: The company's revenue primarily comes from its Surgical & Medical Equipment segment, amounting to CN¥1.20 billion.
Insider Ownership: 29.2%
BMC Medical showcases growth potential with forecasted revenue and earnings growth rates of 20% and 27.4% annually, respectively, surpassing the Chinese market averages. The company trades at a favorable price-to-earnings ratio of 31.8x compared to the market's 41.8x, suggesting good relative value. However, recent FDA regulatory issues concerning device modifications may impact operations. A recent share buyback program indicates proactive capital management despite an unstable dividend record.
- Click to explore a detailed breakdown of our findings in BMC Medical's earnings growth report.
- Our valuation report here indicates BMC Medical may be undervalued.
Caliway Biopharmaceuticals (TWSE:6919)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Caliway Biopharmaceuticals Co., Ltd., along with its subsidiaries, focuses on developing drugs for aesthetic medicine and chronic inflammation, with a market cap of NT$170.42 billion.
Operations: Caliway Biopharmaceuticals Co., Ltd. generates revenue through its focus on drug development for aesthetic medicine and chronic inflammation.
Insider Ownership: 24.4%
Caliway Biopharmaceuticals is positioned for significant growth, with expected annual revenue growth of 111.6%, far outpacing the Taiwan market average. Despite volatile share prices and limited current revenue (NT$38M), the company is forecast to achieve profitability within three years, marking above-average market growth. Recent FDA clearance for pivotal Phase 3 studies of CBL-514 strengthens its clinical development pathway, potentially enhancing its future regulatory success and market potential in fat reduction therapies.
- Dive into the specifics of Caliway Biopharmaceuticals here with our thorough growth forecast report.
- Insights from our recent valuation report point to the potential overvaluation of Caliway Biopharmaceuticals shares in the market.
Taking Advantage
- Investigate our full lineup of 699 Fast Growing Global Companies With High Insider Ownership right here.
- Contemplating Other Strategies? Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com